Literature DB >> 2673770

Familial benign (hypocalciuric) hypercalcemia. A troublesome mimic of mild primary hyperparathyroidism.

H Heath1.   

Abstract

Familial benign hypercalcemia, or hypocalciuric hypercalcemia, may be defined as a dominantly inherited disorder of calcium and magnesium metabolism, characterized by lifelong hypercalcemia and hypermagnesemia (both of variable degree), that usually is not associated with any symptoms, physical signs, reduced vitality, or ill health. Chondrocalcinosis, pancreatitis, gallstones, and neonatal primary hyperparathyroidism are possible rare associations, but findings differ among various studies. The biochemical findings are bland, with "normal" values for serum PTH by many techniques, modest hypophosphatemia, and other findings usually normal. A low calcium:creatinine clearance ratio is suggestive of, but not diagnostic for, FBH; urinary calcium excretion less than 100 mg per day may be just as helpful. The diagnosis should not be made casually or without family screening, because the findings in a given patient may be identical to those in mild primary hyperparathyroidism. The major rationale for careful evaluation is to diagnose the syndrome of FBH and to help affected family members avoid needless expense and the risk of further evaluation and treatment.

Entities:  

Mesh:

Year:  1989        PMID: 2673770

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  10 in total

Review 1.  Familial hypocalciuric hypercalcemia.

Authors:  D A Heath
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Letter to the editor: Distinguishing typical primary hyperparathyroidism from familial hypocalciuric hypercalcemia by using an index of urinary calcium.

Authors:  Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2015-02       Impact factor: 5.958

3.  Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism.

Authors:  S H Pearce; D Trump; C Wooding; G M Besser; S L Chew; D B Grant; D A Heath; I A Hughes; C R Paterson; M P Whyte
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

4.  A case of familial hypocalciuric hypercalcemia type 1 due to CASR p.Pro55Leu mutation.

Authors:  Akira Sumida; Katsumi Iizuka; Takehiro Kato; Yanyan Liu; Sodai Kubota; Saki Kubota-Okamoto; Teruaki Sakurai; Toshinori Imaizumi; Yoshihiro Takahashi; Masami Mizuno; Ken Takao; Takuo Hirota; Tetsuya Suwa; Yukio Horikawa; Mayumi Yamamoto; Yusuke Seino; Atsushi Suzuki; Daisuke Yabe
Journal:  BMC Endocr Disord       Date:  2022-06-22       Impact factor: 3.263

Review 5.  Genetic causes of hypercalciuric nephrolithiasis.

Authors:  Michael J Stechman; Nellie Y Loh; Rajesh V Thakker
Journal:  Pediatr Nephrol       Date:  2008-04-30       Impact factor: 3.714

Review 6.  Physiology and pathophysiology of the calcium-sensing receptor in the kidney.

Authors:  Daniela Riccardi; Edward M Brown
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-18

Review 7.  Familial benign hypercalcemia--from clinical description to molecular genetics.

Authors:  H Heath
Journal:  West J Med       Date:  1994-06

8.  Genetic linkage analysis in familial benign (hypocalciuric) hypercalcemia: evidence for locus heterogeneity.

Authors:  H Heath; C E Jackson; B Otterud; M F Leppert
Journal:  Am J Hum Genet       Date:  1993-07       Impact factor: 11.025

Review 9.  Primary hyperparathyroidism.

Authors:  R Udelsman
Journal:  Curr Treat Options Oncol       Date:  2001-08

10.  Comparison of human chromosome 19q13 and syntenic region on mouse chromosome 7 reveals absence, in man, of 11.6 Mb containing four mouse calcium-sensing receptor-related sequences: relevance to familial benign hypocalciuric hypercalcaemia type 3.

Authors:  Fadil M Hannan; M Andrew Nesbit; Jeremy J O Turner; Joanna M Stacey; Luisella Cianferotti; Paul T Christie; Arthur D Conigrave; Michael P Whyte; Rajesh V Thakker
Journal:  Eur J Hum Genet       Date:  2009-10-07       Impact factor: 4.246

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.